PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Unde	Order the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information diffess it displays a valid owns control indiffeet.								
				Complete if Known					
Sub	stitute for form 1449A/PTO			Application Number	10/785,374				
	NFORMATION DISC	0	IIDE	Filing Date	2/24/2004				
-				First Named Inventor	Summar et al.				
	STATEMENT BY APP	LIC	ANI	Art Unit	1638				
	(Use as many sheets as nece	ssary)		Examiner Name Diana B. Johannsen					
Sheet 1 of 7				Attorney Docket Number	1242/58 CIP				

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
Initials*	No.1	Number - Kind Code ^{2 (V known)}	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
	ļ							
		-						

	FOREIGN PATENT DOCUMENTS							
Examiner		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T ⁶		
	1	EP 044119 A2	08-14-1991	Levere et al.				
						-		
						1		

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for form 1449B/PTO			Complete if Known				
Gubbin	ate for form 1445Bit 10			Application Number	10/785,374			
INF	ORMATION DISC	a os	SURF	Filing Date	2/24/2004			
	ATEMENT BY AF			First Named Inventor	Summar et al.			
317	A I CIVICINI DI AF	FLIC	MINI	Art Unit	1638			
	(Use as many sheets as ne	cessary)		Examiner Name	Diana B. Johannsen			
Sheet	2	of	7	Attorney Docket Number	1242/58 CIP			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	Abman et al., "Role of endothelium-derived relaxing factor during transition of the pulmonary circulation at birth," Am. J. Physiol., Vol. 259, pgs. H1921-H1927 (1990).	
	3	Abman, S. H.; Arch Dis Child Fetal Neonatal Ed (2002) 87: F15-F18.	
	4	Adelman et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000- Dalton Form of Human Pituitary Growth Hormone," DNA, Vol. 2, pg. 183-193 (1983).	
	5	Advisory Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated March 9, 2011.	
	6	Allen, J. and ATS subcommittee AoP, Am J Respir Crit Care Med (2003) 168: 356-396.	
	7	Artymiuk et al., "Biotin carboxylase comes into the fold," Nature Struct. Biol., Vol. 3, pgs. 128-132 (1996).	
	8	Bachmann et al., New England Journal of Medicine, Vol. 304, pg. 543 (1981).	
	9	Batshaw and Brusilow, "Valproate-induced hyperammonemia," Annals of Neurology, Vol. 11, No. 3, pgs. 319-21 (1982).	
	10	Bearman, S.I., "Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation," Journal of Clinical Oncology, Vol. 11, pgs. 1729-1736 (1993).	
	11	Beaucage et al., "Deoxynucleoside phosphoramidites - a new class of key intermediates for deoxypolynucleotide synthesis," Tetrahedron Letters, Vol. 22, pgs. 1859-1862 (1981).	
	12	Beaumier, L., "Arginine: New and exciting developments for an 'old' amino acid," Biomedical & Environmental Sciences, Vol. 9, pgs. 296-315 (1996).	
	13	Becker et al., Archives of Biochemistry & Biophysics, Vol. 223, pgs. 381-392 (1983).	
	14	Bernard et al., Intensive Care Medicine, Vol. 20, pgs. 225-32 (1994).	
	15	Boger, R. H., Curr Opin Clin Nutr and Met Care (2008) 11:55-61.	
	16	Bourrier et al., Prese Medicale, Vol. 17, pgs. 2063-2066 (1988).	
	17	Caroline et al., "Acute L-arginine supplement and cardiac surgery," Canadian J. Anesth., Vol. 43, pg. A16 (1996).	
	18	Castillo et al., "Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension," Pediatr. Res., Vol. 38, pgs. 17-24 (1995).	
	19	Castillo et al., Journal of Biological Chemistry, Vol. 264, pgs. 4038-44 (1989).	
	20	Castro-Gago et al., Child Neuro Systems, Vol. 6, pgs. 434-436 (1990).	
	21	Cervera et al., "Photoaffinity labeling with UMP of lysine 992 of carbamyl phosphate synthetase from Escherichia coli allows identification of the binding site for the pyrimidine inhibitor," Biochemistry, Vol. 35, pgs. 7247-7255 (1996).	

Examiner	Date	ı
Signature	Considered	J
*EXAMINER: In	ial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not	_

*EXAMINEE: Initial inference considered, whether on of citation is no conformance with MPEP 000. Draw line through citation if not in conformance and not considered, include copy of this form in hex dominimation in applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language this properties of the public which is to file (and by the USPTO to process) an application. Controlled the properties of the information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Controlled the properties of the information is controlled to process an application, and submitting the completed application from the full USPTO. Time will way depending upon the individual case. Any comments on the amount of time you require to complete depolations from the full USPTO. Time will way depending upon the individual case. Any comments on the amount of time you require to commence, Po do suggestions for reducing this back, sould be sent for the file information. Office, U.S. Padern and Trademark Office, U.S. Department of Commerce, P.O. State (449, Abassariah), W. 2213-1460. DO NOT SEND FEE OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTOSS[68] 07.03

Approved for use through 073/12012, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it dispays a valid UMB coorder furniber.

Subetitu	te for form 1449B/PTO			Complete if Known		
Oubstitu	to for form 1440bit 10			Application Number	10/785,374	
INF	ORMATION DIS	CLOS	LIRE	Filing Date	2/24/2004	
	TEMENT BY A			First Named Inventor	Summar et al.	
317	ALEMENT DI A	FFLIC	AINI	Art Unit	1638	
	(Use as many sheets as	necessary)		Examiner Name	Diana B. Johannsen	
Sheet 3 of 7		Attorney Docket Number	1242/58 CIP			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	22	Cheung et al., "Channeling of Urea Cycle Intermediates in Situ in Permeabilized Hepatocytes," J. Biol. Chem., Vol. 264, pgs. 4038-4044 (1989).	
	23	Cohen P. P., Current Topics in Cellular Regulation, Vol. 18, pgs. 1-19 (1981).	
	24	Conner et al., Proc. Natl. Acad. Sci. U.S.A. 80:278(1983).	
	25	Coude et al., J. Clin. Invest., Vol. 64, pgs. 1544-1551 (1979).	
	26	Coulter et al., Lancet, Vol. 1, No. 8181, pgs. 1310-1311 (1980).	
	27	Crea et al., Proc. Natl. Acad. Sci. USA, Vol. 75, pgs. 5765-5769 (1978).	
	28	de Groot et al., Biochemical & Biophysical Research Communications, Vol. 124, pgs. 882-888 (1984).	
	29	Eadle et al., "Valproate-associated hepatotoxicity and its biochemical mechanisms," Med. Toxicol., Vol. 3, pgs. 85-106 (1998).	
	30	Eichenlaub et al., "Mutants of the mini-F plasmid pML31 thermosensitive in replication," J. Bacteriol., Vol. 138, pgs. 559-566 (1979).	
	31	Faber-Langendoen et al., Bone Marrow Transplantation, Vol. 12, pgs. 501-507 (1993).	
	32	Fike, C. D. et al., J Appl Physiol (2000) 88:1797-1803.	
	33	Fike, C. D., et al., American Journal of Physiology (Lung, Cellular and Molecular Physiology 18) (1998) 274:L517-L526	
	34	Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins," Nucl. Acids. Res., Vol. 14, pgs. 6745-6763 (1986).	
	35	Hauser et al., "Allopurinol-induced orotidinuria," New England Journal of Medicine, Vol. 322, pgs. 1641-1645 (1990).	
	36	Hebert, P.C., "A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome," Chest, Vol. 104, pgs. 230-235 (1993).	
	37	Jackson M. J., Annual Review of Genetics, Vol. 20, pgs. 431-64 (1986).	
	38	Javid-Majd et al., "Comparison of the Functional Differences for the Homologous Residues within the Carboxy Phosphate and Carbamate Domains of Carbamoyl Phosphate Synthetase," Biochemistry, Vol. 35, pgs. 14362-14369 (1996).	
	39	Jones et al., "Venoocclusive disease of the liver following bone marrow transplantation," Transplantation, Vol. 44, pgs. 778-783 (1987).	
	40	Kamoun et al., "Valproate-induced inhibition of urea synthesis," Lancet, Vol. 1, pg. 48 (1987).	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 30 Cs. 12 and 37 CPR 1.14. This collection is estimated to blaze 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Diana B. Johannsen

1242/58 CIP

Under the Papework Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 14498/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date

2/24/2004

Filing Date

2/24/2004

Filing Date

1/383

1/38

Examiner Name

Attorney Docket Number

(Use as many sheets as necessary)

of 7

4

Sheet

Examiner

		NON PATENT LITERATURE DOCUMENTS	
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, citly and/or country where publisher.	T ²
	41	Kinsella et al., "Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn," Lancet, Vol. 340, pgs. 819-820 (1992)	
	42	Kyte & Doolittle, "A simple method for displaying the hydropathic character of a protein," J. Mol. Biol., Vol. 157, pgs. 105-132 (1982).	
	43	Landgren et al., Science, 241:1007, (1988).	
	44	Landgren et al., Science, 242:229-237, (1988).	
	45	Lipsitz et al., "Endogenous nitric oxide and pulmonary vascular tone in the neonate," J. Pediatr. Surg., Vol. 31, pgs. 137-140 (1996)	
	46	Liu and Sommer, "Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA," Biotechniques, Vol. 18, No. 3, pgs. 470-477 (1995).	
	47	Liu, et al., Am J Physiol Lung Cell Mol Physiol (2006) 290:L2-L10.	
	48	Maniatis et. al., in <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor, N.Y., pgs. 280-281 (1982).	
	49	Marrini et al., "Hepatic and renal contributions to valproic acid-induced hyperammonemia," Neurology, Vol. 38, pgs. 365-371(1988).	
	50	Marshall et al., "Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome," Critical Care Medicine, Vol. 23, pgs. 1638-1652 (1995).	
	51	Matuschak and Rinaldo, "Organ interactions in the adult respiratory distress syndrome during sepsis. Role of the liver in host defense," Chest, Vol. 94, pgs. 400-406 (1988).	
	52	Matuschak et al., American Review of Respiratory Disease, Vol. 141, pgs. 1296-1306 (1990).	
	53	Matuschak, G. M., "Lung-liver interactions in sepsis and multiple organ failure syndrome," Clinics in Chest Medicine, Vol. 17, pgs. 83-98 (1996).	
	54	McCaffrey et al., "Effect of L-Arginine Infusion on Infants with Persistent Pulmonary Hypertension of the Newborn," Biol. Neonate, Vol. 67, No. 4, pgs. 240-243 (1995).	
	55	McDonald et al., "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients," Annals of Internal Medicine, Vol. 118, pgs. 255-267 (1993).	
	56	Meier, U., Pharm Stat (2006) 5:253-263.	
	57	Meister, A., "Mechanism and regulation of the glutamine-dependent carbamyl phosphate synthetase of Escherichia coli.," Adv. Enzymol. Relat. Areas Mol. Biol., Vol. 62, pgs. 315-374 (1989).	

Signature		Considered	
*EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citat	on if not in conformance and not

Date

Excellence. Intellal interestive Consection, winestern Violution for an introductionate with refer to the consection and intelligence of the consection of t

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
Cobount				Application Number	10/785,374	
INF	ORMATION DISC	a os	SURF	Filing Date	2/24/2004	
STATEMENT BY APPLICANT				First Named Inventor	Summar et al.	
317	ALEMENT DI AP	PLIC	ANI	Art Unit	1638	
	(Use as many sheets as ne	cessary		Examiner Name	Diana B. Johannsen	
Sheet	5	of	7	Attorney Docket Number	1242/58 CIP	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	58	Messing et al., Third Cleveland Symposium on Macro Molecular and Recombinant DNA, Ed. Walton, A., (Elsevier, Amsterdam) (1981).				
	59	Mitchell et al., "Syndrome of Idiopathic Hyperammonemia after High-Dose Chemotherapy: Review of Nine Cases," American Journal of Medicine, Vol. 85, No. 5, pgs. 662-667 (1988).				
	60	Moncada et al., "The L-Arginine-Nitric Oxide Pathway," New England Journal of Medicine, Vol. 329, pgs. 2002-2012 (1993).				
	61	Moorman et al., "Expression patterns of mRNAs for ammonia-metabolizing enzymes in the developing rat: the ontogenesis of hepatocyte heterogeneity," Histochemical Journal, Vol. 22, pgs. 457-468 (1990).				
	62	Mupanemunda, R. H., Early Human Development (1997) 47: 247-262.				
	63	Needleman et al., "A general method applicable to the search for similarities in the amino acid sequence of two proteins," J. Mol. Biol., Vol. 48, pgs. 443-453 (1970).				
	64	Nuzum, "Urea Cycle Enzyme Adaptation to Dietary Protein in Primates," Science, Vol. 172, pgs. 1042-1043 (1971).				
	65	Office Action corresponding to U.S. Patent Application Serial No. 12/322,434 dated April 5, 2011.				
	66	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated March 23, 2011.				
	67	Office Action corresponding to EP Patent Application Serial No. 10184493 dated March 30, 2011				
	68	Office Action corresponding to EP Patent Application Serial No. 05723789 dated March 31, 2011				
	69	Palmer et al., "L-Arginine is the Physiological Precursor for the Formation of Nitric Oxide in Endothelium-Dependent Relaxation," Biochem. Biophys. Res. Commun., Vol. 153, pgs. 1251-1256 (1988).				
	70	Pierson, D.L., "A rapid colorimetric assay for carbamyl phosphate synthetase I," J. Biochem. Biophys. Methods, Vol. 3, pgs. 31-37 (1980).				
	71	Price et al, "Prognostic Indicators for Blood and Marrow Transplant Patients Admitted to an Intensive Care Unit," American Journal of Respiratory & Critical Care Medicine, Vol. 158, pgs. 876-884 (1998).				
	72	Rabier et al., "Effects of organic acids on the synthesis of citrulline by intact rat liver mitochondria," Biochimie, Vol. 68, pgs. 639-647 (1986).				
	73	Rabier et al., "Propionate and succinate effects on acetyl glutamate biosynthesis by rat liver mitochondria," Biochem. & Biophys. Research Comm., Vol. 91, pgs. 456-460 (1979).				

Examiner	Date
Signature	Considered
	and the state of t

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicants unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CPR 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including за учиствення применя и применя и пответняют у в доменен в учиствення учиствення и применен в прим

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Panenuor's Reduction Act of 1995, no necessary are require

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/785,374	
INF	ORMATION DISC	CLOS	SURF	Filing Date	2/24/2004	
	ATEMENT BY AP			First Named Inventor	Summar et al.	
317	ATEMICITED I AF	FLIC	ZANI	Art Unit	1638	
	(Use as many sheets as nec	cessary)		Examiner Name	Diana B. Johannsen	
Sheet	6	of	7	Attorney Docket Number	1242/58 CIP	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	74	Raiha and Suihkonen, J. Acta Paediatrica Scand., Vol. 57, pgs. 121-127 (1968).	
	75	Richardson et al., "Prevention and treatment of hepatic venocclusive disease after high- dose cytoreductive therapy," Leukemia & Lymphoma, Vol. 31, pgs. 267-277 (1998).	
	76	Rinaldo et al., "Nitri oxide inactivates xanthine dehydrogenase and xanthine oxidase in interferon-gamma-stimulated macrophages," American Journal of Respiratory Cell & Molecular Biology, Vol. 11, pgs. 625-630 (1994).	
	77	Roberts, J. D., et al., "Inhaled nitric oxide in persistent pulmonary hypertension of the newborn," Lancet, Vol. 340, pgs. 818-819 (1992)	
	78	Rodriguez-Aparicio, L. B. et al., Biochemistry, Vol. 28, pgs. 3070-3074 (1989).	
	79	Rubio, V., (Review) Biochemical Society Transactions, Vol. 21, pgs. 198-202 (1993).	
	80	Salki et al., "A Novel Method for the Detection of Polymorphic Restriction Sites by Cleavage of Oligonucleotide Probes: Application to Sickle-Cell Anemia," Bio/Technology, Vol. 3, pgs. 1008-1012 (1985).	
	81	Schmid, R. D., Clin. Chim. Acta., Vol. 74, pgs. 39-42 (1977).	
	82	Schwartz et al., eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 357-358 (1979).	
	83	Shigesada et al., Journal of Biological Chemistry, Vol. 246, pgs. 5588-5595 (1971).	
	84	Shimoda L., et al., Physiol Res (2000) 49:549-560.	
	85	Shulman et al., "Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms," Hepatology, Vol. 19, pgs. 1171-81 (1994).	
	86	Smith et al., "Comparisons of biosequences," Adv. Appl. Math., Vol. 2, pgs. 482-489 (1981).	
	87	Stapleton et al., "Comparison of the Functional Differences for the Homologous Residues Within the Carboxy Phosphate and Carbamate Domains of Carbamoyl Phosphate Synthetase," Biochemistry, Vol. 35, pg. 14352-14361 (1996).	
	88	Subhedar, N. V., Acta Paediatr suppl (2004) 444:29-32.	
	89	Summar ML, et al., "Physical and linkage mapping of human carbarnyl phosphate synthetase I (CPS1) and reassignment from 2p to 2q35," Cytogenetics & Cell Genetics, Vol. 71, pgs. 266-267 (1995).	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EXAMINEE: Inflail infederance considered, whether or not clastion is in conformance with MPEP 600. Draw live through citation if not conformance and not considered. Include copy of this form with the act communication to applicant.
Applicant's unique citation estimates the experiment of the special conformance and not considered. Applicant's unique citation estimates of the experiment of the special citation estimates of the public which is to file (and by the USPTO 15 not societion of International in required by 30° CRF 1.9 n. His formation is required to obtain or retain a benefit by the public which is to file (and by the USPTO 15 not confiderable), and is confiderable to complete, including a special confiderable and in the confiderable and in the confiderable and in the confiderable and in the complete application from the USPTO. Three will very opening upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for rectuing this bench, should be sent to the Chief Internation Officer, U.S. Patert and Thomas and Chief. U.S. Department of Commence, P.O. Since 1469, Alexandrish, W. 22313-1460, D.O. MOT SEND FEES OR COMPLETED FORMS TO THIS Training and Chief. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE

Unc	ier the Paperwork Reduction Act	of 1995,	no persons are	required to respond to a collectlor	of information unless it displays a valid OMB control number		
Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/785,374		
INF	ORMATION DISC	a os	SURF	Filing Date	2/24/2004		
				First Named Inventor	Summar et al.		
STATEMENT BY APPLICANT				Art Unit	1638		
	(Use as many sheets as ne	cessary)		Examiner Name	Diana B. Johannsen		
Sheet	7	of	7	Attorney Docket Number	1242/58 CIP		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	90	Summar, M. L., "Molecular genetic research into carbamoyl-phosphate synthase I: molecular defects and linkage markers," Journal of Inherited Metabolic Disease, Vol. 21, Suppl. 1, pgs. 30-39 (1998).	
	91	Toh et al., European Journal of Biochemistry, Vol. 215, pgs. 687-696 (1993).	
	92	Tse et al., "Hyperammonemia following allogeneic bone marrow transplantation," American Journal of Hematology, No. 38, pgs. 140-141 (1991).	
	93	Turley, J. E. et al., Am J Physiol Lung Cell Mol Physiol (2003) 284:L489-L500.	
	94	van den Hoff et al., "Evolutionary relationships of the carbamoylphosphate synthetase genes," Journal of Molecular Evolution, Vol. 41, pgs. 813-832 (1995).	
	95	Vosatka et al., "Arginine Deficiency Accompanies Persistent Pulmonary Hypertension of the Newborn," Biol. Neonate, Vol. 66, pgs. 65-70 (1994)	
	96	Warter et al., Revue Neurologique, Vol. 139, pgs. 753-757 (1983).	
	97	Wetmur & Davidson, J. Mol. Biol., Vol. 31, pgs. 349-370 (1968).	
	98	Wingard et al., Bone Marrow Transplantation, Vol. 4, pgs. 685-9 (1989).	
	99	Zamora et al., "Plasma L-arginine concentration, oxygenation index, and systemic blood pressure in premature infants," Crit. Care Med., Vol. 26, pgs. 1271-1276 (1998).	
			_
	-		
			_
	1		-
			┝

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"EXAMINET: Initial if reference considered, whether or not citation is in conformance with MFEP 600. Draw line Brough citation if not in conformance and not considered. Include copy of this form with head communication to applicant.

Applicant's unique citation designation number (epithosa). "Applicant is to place a check mark hern I English prouper Tensistion is attached.

Applicant's unique citation designation number (epithosa). "Applicant is to place a check mark hern I English prouper Tensistion is attached.

Applicant's unique citation designation and the complexed of the citation of the complexed of the citation is designed by the public which is to fis (and by the USPTO to process) an application. Confidentially is governed by 38 U.S. C. 12 and 75 CPT 14.1. This collection is estimated to lake 24 hours to propriete, including gathering, preparing, and submitting the complexed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the mount of time you requise to complete the fish form and/or suggestions for reducing this burden, should be sent to the Chief information Officer. Jestert and Trademark Office, U.S. Department of Committee, P.O. Box 1469, Alexandria, VA 2231-1469. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissions for Potentia, P.O. Dos 1469, Alexandria, VA 2231-1469.